Axios @axios
Heart medications Vyndaqel and Vyndamax generated $1.3 billion of global revenue last year for Pfizer and already brought in $453 million in Q1 of this year. The blockbuster drugs could grow significantly more if Pfizer wins a pending lawsuit. https://t.co/FSi20Zhqmq — PolitiTweet.org